研究發現醫療大麻對治療心理健康疾病並無實證支持
Study Finds No Evidence for Medical Cannabis in Treating Mental Health Disorders
雪梨大學馬蒂爾達中心（Matilda Centre）發表於《刺胳針精神病學》（The Lancet Psychiatry）的一項里程碑式研究，對近年來在心理健康領域日益盛行的醫用大麻提出了質疑。
A landmark study published in The Lancet Psychiatry by the University of Sydney’s Matilda Centre has challenged the growing popularity of medical cannabis for mental health.
研究人員在審閱了 54 項、涵蓋超過 2,000 名受試者的臨床試驗後發現，沒有強有力的證據顯示醫用大麻能有效治療焦慮、憂鬱或創傷後壓力症候群（PTSD）。
After reviewing 54 clinical trials involving over 2,000 participants, researchers found no strong evidence that medicinal cannabis effectively treats anxiety, depression, or PTSD.
雖然有一些低品質的證據顯示其對於失眠或自閉症等病症可能有潛在益處，但相關數據仍然不足。
While some low-quality evidence suggests potential benefits for conditions like insomnia or autism, the data remains insufficient.
重要的是，研究強調與安慰劑相比，使用大麻與更高的不良副作用風險相關。
Importantly, the study highlights that cannabis use is linked to a higher risk of adverse side effects compared to a placebo.
儘管大麻被視為一種「低風險」選項，但目前常規使用醫用大麻治療這些疾患大多缺乏正當性。
Despite its reputation as a 'low-risk' option, the routine use of medicinal cannabis for these disorders is currently rarely justified.
